Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Champions Oncology revenue
Champions Oncology's revenue is $50.2 million.
What is Champions Oncology's revenue?
- Champions Oncology's revenue growth from 2008 to 2024 is 3,482.5%.
- Champions Oncology has 115 employees, and the revenue per employee ratio is $436,130.
- Champions Oncology's peak quarterly revenue was $17.0M in 2025(q3).
- Champions Oncology peak revenue was $53.9M in 2023.
- Champions Oncology annual revenue for 2023 was 53.9M, 9.69% growth from 2022.
- Champions Oncology annual revenue for 2024 was 50.2M, -6.9% growth from 2023.
On this page
Zippia finds jobs where you're a top candidate and applies on your behalf.
Champions Oncology historical revenue
Champions Oncology's peak revenue was $53.9M in 2023. The peak quarterly revenue was $17.0M in 2025(q3).
Champions Oncology's revenue increased from $1.4m in 2008 to $50.2M currently. That's a 3,482.5% change in annual revenue.
Champions Oncology annual revenue
Champions Oncology annual revenue over time
| Fiscal year / year | Champions Oncology revenue |
|---|---|
| 2009 | $3.7M |
| 2010 | $4.9M |
| 2011 | $6.9M |
| 2012 | $7.1M |
| 2013 | $8.3M |
| 2014 | $11.6M |
| 2015 | $8.9M |
| 2016 | $11.2M |
| 2017 | $15.4M |
| 2018 | $20.2M |
| 2019 | $27.1M |
| 2020 | $32.1M |
| 2021 | $41.0M |
| 2022 | $49.1M |
| 2023 | $53.9M |
| 2024 | $50.2M |
How accurately did Champions Oncology's revenue projections match actual performance?
Champions Oncology annual growth
Champions Oncology saw the greatest revenue growth in 2009, when revenue increased by 165.0%.
Champions Oncology had the lowest revenue growth in 2015, when revenue changed by -23.26%.
Champions Oncology annual growth rate over time
| Year | Champions Oncology growth |
|---|---|
| 2009 | 165%↑ |
| 2010 | 32%↑ |
| 2011 | 41%↑ |
| 2012 | 4%↑ |
| 2013 | 16%↑ |
| 2014 | 39%↑ |
| 2015 | -23%↓ |
| 2016 | 26%↑ |
| 2017 | 38%↑ |
| 2018 | 31%↑ |
| 2019 | 34%↑ |
| 2020 | 19%↑ |
| 2021 | 28%↑ |
| 2022 | 20%↑ |
| 2023 | 10%↑ |
| 2024 | -7%↓ |
Champions Oncology quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
Champions Oncology quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2009 | $673,000 | $1.0M | $984,000 | $1.0M |
| 2010 | $962,000 | $1.3M | $742,000 | $1.9M |
| 2011 | $1.6M | $933,000 | $2.8M | $1.5M |
| 2012 | $1.6M | $1.7M | $2.4M | $1.4M |
| 2013 | $2.1M | $1.5M | $2.9M | $1.8M |
| 2014 | $3.0M | $2.4M | $3.7M | $2.5M |
| 2015 | $1.9M | $1.9M | $1.8M | $3.2M |
| 2016 | $2.8M | $3.0M | $2.6M | $2.8M |
| 2017 | $3.7M | $4.5M | $3.6M | $3.7M |
| 2018 | $5.0M | $5.2M | $5.1M | $4.9M |
| 2019 | $6.2M | $6.7M | $6.4M | $7.7M |
| 2020 | $6.7M | $7.6M | $9.0M | $8.7M |
| 2021 | $9.5M | $10.1M | $10.8M | $10.6M |
| 2022 | $11.3M | $11.8M | $13.2M | $12.9M |
| 2023 | $13.7M | $14.3M | $12.8M | $13.1M |
| 2024 | $12.6M | $11.6M | $12.0M | $14.0M |
| 2025 | $14.1M | $13.5M | $17.0M | - |
Champions Oncology jobs nearby
Do you work at Champions Oncology?
Is Champions Oncology transparent about its revenue structure?
Champions Oncology financial information
| Industry | Commercial & Professional Services |
| Company Type | Public |
| Employees Number | 115 |
| Date Founded | 1985 |
| Headquarters | Hackensack, New Jersey |
| Number of Locations | 3 |
| Revenue | $50.2M |
| Net Income | -$5,335,000 |
| Gross Proft | $20.8M (2024) |
| PE Ratio | -13.15 |
| Tax Rate | 0.0% |
| Market Capitalization | $95.7M |
| Total Assets | $34,311,000 |
| Ticker | CSBR |
Champions Oncology jobs you might like
Champions Oncology financing
Champions Oncology received early financing of $2.1M on 2010-01-05.
| Series | Round size | Date |
|---|---|---|
| Post Ipo Equity | $2.1M | 01/2010 |
| Post Ipo Equity | $9.4M | 04/2011 |
| Post Ipo Equity | $9.3M | 02/2013 |
| Post Ipo Debt | $2M | 12/2014 |
| Post Ipo Equity | $14M | 03/2015 |
Champions Oncology investors
| Investors | Security type |
|---|---|
| New Enterprise Associates (NEA) | Post Ipo Equity |
| Perceptive Advisors | Post Ipo Equity |
| Sabby Capital | Post Ipo Equity |
| Battery Ventures | Post Ipo Equity |
Champions Oncology competitors
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Radiometer | $47,494 | $32.1M | 77 | - |
| Tetracore | $51,847 | $17.5M | 50 | - |
| Cytokinetics | $89,800 | $18.5M | 130 | 22 |
| RUCDR | $50,314 | $8.5M | 150 | - |
| Metabolix | $53,987 | $9.1M | 50 | - |
| Acceleron Pharma | $70,914 | $92.5M | 312 | - |
| Genocea | $53,221 | - | 59 | - |
| TECHLAB, Inc. | $46,450 | $25.0M | 100 | - |
| Integrity Bio | $81,716 | $11.0M | 125 | - |
| BioReliance | $74,348 | $49.9M | 700 | - |
Search for jobs
Related company revenues
Working at related companies
Related company jobs
Champions Oncology highest paying jobs
Zippia gives an in-depth look into the details of Champions Oncology, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Champions Oncology. The employee data is based on information from people who have self-reported their past or current employments at Champions Oncology. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Champions Oncology. The data presented on this page does not represent the view of Champions Oncology and its employees or that of Zippia.
Champions Oncology may also be known as or be related to CHAMPIONS ONCOLOGY INC., CHAMPIONS ONCOLOGY, INC., Champion Oncology, Inc., Champions Oncology, Champions Oncology Inc and Champions Oncology, Inc.